United Laboratories International Holdings (HKG:3933) said the marketing registration application for the Insulin Degludec and Liraglutide Injection was accepted by China's National Medical Products Administration.
The drug, self-developed by unit Zhuhai United Bio-Pharmaceutical, is for glycemic control and weight management, a Thursday bourse filing showed.